Will Czech scientists change the paradigm of treatment of "high-risk" myelodysplastic syndrome?
It is more than half a year since the results of an academic prospective randomized clinical trial, which was organized thanks to the collaboration of the BIOCEV Centre and the 1st Internal Medicine Clinic of the 1st Faculty of Medicine of the Charles University in Prague, were published in the Blood Cancer Journal, and which brought an innovative approach to the treatment of patients with myelodysplastic syndrome (MDS) in transition to acute myeloid leukemia (AML).
Since then, an increasing number of domestic and international haematology departments have become interested in the new treatment protocol, which improves the effectiveness of DNA demethylation therapy while maintaining safety. At the same time, more interesting findings are on the horizon that could help address the therapeutic resistance of these serious diseases in the future.
Source (in Czech): Medical Tribune
BIOCEV Official Press Release: HERE